Resorbable Magnesium Scaffolds Registry | NCT04679740 | Trialant

Resorbable Magnesium Scaffolds Registry | NCT04679740 | Trialant

Arms/Interventions Module

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Magmaris	Device	MAGMARIS is indicated for improving luminal diameter in the treatment of de novo native coronary artery lesions in patients with symptomatic coronary artery disease. The reference vessel diameter should closely match the scaffold nominal diameter. The treated lesion length should be less than the nominal scaffold length.		Magmaris Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold
Freesolve	Device	Freesolve is indicated for improving luminal diameter in the treatment of de novo native coronary artery lesions in patients with symptomatic coronary artery disease. The reference vessel diameter should closely match the scaffold nominal diameter. The treated lesion length should be less than the nominal scaffold length.		Freesolve Sirolimus-Eluting Coronary Resorbable Magnesium Scaffold (RMS) System

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Target Lesion Failure (TLF)	The primary endpoint will be Target Lesion Failure (TLF) at 12 months. TLF is a composite of Cardiac Death, Target Vessel Q-wave or non-Q wave MI, or clinically driven Target Lesion Revascularization (TLR).	12 months

Contacts/Locations Module

References Module

Citations

PubMed Identifier	Type	Citation	Retractions
42368841	Derived	Wolbert S, Schmidt T, Wittek F, Mayer B, Raake P, Bongiovanni D, Torzewski J. One-year outcomes of bioresorbable magnesium scaffold implantation in complex coronary lesions. Front Cardiovasc Med. 2026 Jun 12;13:1854686. doi: 10.3389/fcvm.2026.1854686. eCollection 2026.

Condition Browse Module